Skip to main content

Advertisement

SpringerLink
Log in

Development of a novel prediction model for recurrent stage II colon cancer

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Adjuvant chemotherapy is recommended for patients with high-risk stage II colon cancer. High-risk stage II is defined by clinicopathological factors in some guidelines. However, there is no unified definition. The aim of this study was to examine the risk factors and develop a novel model to predict the recurrence of stage II colon cancer.

Methods

Three hundred fifty patients who underwent curative resection for stage II colon cancer at Osaka International Cancer Institute and Yao Municipal Hospital from 2004 to 2012 were included. Clinicopathological factors were assessed in a subgroup of 298 patients (Learning Set), and the relapse-free survival (RFS) rate was evaluated as the main outcome. A statistical analysis was performed using a proportional hazards model to determine the factors associated with RFS and a nomogram was developed to predict recurrence. A second subgroup of 52 independent patients who underwent curative resection in 2012 (Validation Set) was used to validate the nomogram.

Results

The median RFS time was 4.96 years, and recurrence was observed in 35 patients. A univariate analysis revealed that a high serum CEA level, preoperative occlusion, tumor location (left-side colon), lymphatic invasion, and vascular invasion were significantly correlated with RFS. These variables were used to develop the nomogram. The C-index was 0.701 in the learning set and 0.585 in the validation set. Using nomogram points, the patients were classified into low-risk, middle-risk, and high-risk categories.

Conclusion

A recurrence prediction model was developed that integrated multiple risk factors in stage II colon cancer patients. High-risk patients were identified by the nomogram.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Soerjomataram I, Lortet TJ, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840–50.

    Article  Google Scholar 

  2. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.

    Article  Google Scholar 

  3. Hall WH. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–500.

    Article  Google Scholar 

  4. Bjom C, Hemming J, Ake R, Lars ER, Tolle T, Wilking Nils. Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer. 1990;66:49–55.

    Article  Google Scholar 

  5. Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, Rooney PS, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174–83.

    Article  Google Scholar 

  6. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation––technical notes and outcome. Colorectal Dis. 2009;11:354–65.

    Article  CAS  Google Scholar 

  7. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl Med. 1990;322:352–8.

    Article  CAS  Google Scholar 

  8. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

    Article  CAS  Google Scholar 

  9. Verhoeff SR, Erning FN, Lemmens VE, Wilt JH, Pruijt JF. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 2016;139:187–93.

    Article  CAS  Google Scholar 

  10. Laffer U, Metzger U, Aeberhard P, Maibach R, Castiglione M, Goldhirsch A, et al. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet. 1995;345:349–53.

    Article  Google Scholar 

  11. Erlichman C. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17:1356–63.

    Article  Google Scholar 

  12. The Colorectal Cancer Chemotherapy Study Group of Japan. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. Jpn Clin Oncol. 1995;25:91–103. https://doi.org/10.1093/oxfordjournals.jjco.a039761.

    Article  Google Scholar 

  13. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13:2936–43.

    Article  CAS  Google Scholar 

  14. Taal BG, Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: Improved survival in stage II and III. Br J Cancer. 2001;85:1437–43.

    Article  CAS  Google Scholar 

  15. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34.

    Article  Google Scholar 

  16. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Cin Oncol. 2004;22:3408–19.

    Article  Google Scholar 

  17. Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:370–98.

    Article  CAS  Google Scholar 

  18. Schmoll HJ, Cutsem E, Stein A, Valentini V, Haustermans K, Glimelius B, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer a personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.

    Article  CAS  Google Scholar 

  19. Li K, Wang R, Huang S, Pan X, Chen H, Zhou L, et al. Prognostic nomogram for overall survival in extranodal natural killer/T-cell lymphoma patients. Clin Lymphoma Myeloma Leuk. 2018;18:537–43.

    Article  Google Scholar 

  20. Miyoshi N, Ohue M, Yasui M, Noura S, Shingai T, Sugimura K, et al. Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection. ESMO Open. 2016. https://doi.org/10.1136/esmoopen-2016-000052.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Harrell FE, Robert MC, David BP, Kerry LL, Rodert AR. Evaluating the yield of medical tests. JAMA. 1982;247:2543–6.

    Article  Google Scholar 

  22. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet. 2007;370:2020–9.

    Article  Google Scholar 

  23. Labianca R, Marsoni S, Pancera G, Torri V, Zaniboni A, Erlichman C, et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939–44.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Osaka International Cancer Institute, Osaka, 541-8567, Japan

    Yuya Takenaka, Norikatsu Miyoshi, Yusuke Takahashi, Junichi Nishimura, Masayoshi Yasui & Masayuki Ohue

  2. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan

    Norikatsu Miyoshi & Shiki Fujino

  3. Department of Surgery, Yao Municipal Hospital, Yao, Osaka, 581-0069, Japan

    Yoshihito Ide, Hajime Hirose & Masayoshi Tokuoka

Authors
  1. Yuya Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norikatsu Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shiki Fujino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yusuke Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junichi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masayoshi Yasui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihito Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hajime Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayoshi Tokuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masayuki Ohue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norikatsu Miyoshi.

Ethics declarations

Conflicts of interest

The authors declare no conflict of interest in association with the present study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takenaka, Y., Miyoshi, N., Fujino, S. et al. Development of a novel prediction model for recurrent stage II colon cancer. Surg Today 50, 389–395 (2020). https://doi.org/10.1007/s00595-019-01897-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-019-01897-4

Keywords

Search

Navigation